ASCO 2022 | Remaining questions on the use of neoadjuvant pembrolizumab in early TNBC following KEYNOTE-522
Lajos Pusztai, MD, DPhil, Yale School of Medicine, New Haven, CT, talks on the results of the Phase III KEYNOTE-522 (NCT03036488) trial exploring residual cancer burden after neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for early triple-negative breast cancer (TNBC). Approximately 5% of patients had extensive residual disease prior to surgery. These patients did not derive benefit with or without the addition of pembrolizumab and exhibited high rates of recurrence. To increase cost effectiveness, the identification of a biomarker to select patients who will benefit most from the addition of pembrolizumab is in progress. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
